This collaboration aims to combine Molcure’s cutting-edge AI technology with Boehringer Ingelheim’s extensive expertise in drug discovery
It represents a 30% increase in the company’s production capacity and introduces a segment dedicated to highly potent active ingredients
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
The new site enables end-to-end production of viral vector gene therapies
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
IND application for EB-003 expected in early 2026
Subscribe To Our Newsletter & Stay Updated
